Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $515.44 +0.17%
EPS Growth %: 0.0%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: 0.0%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.98, $0.04 worse than the analyst estimate of $4.02. Revenue for the quarter came in at $2.91 billion versus the consensus estimate of $2.79 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.75-12 billion, versus the consensus of $11.85 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
